ReviewNature reviews. Disease primers2025
Cushing syndrome.
Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).European journal of endocrinology · 2025Trial
- Hydrogel-based lineage-specific gene therapy prevents recurrence of corticotroph tumors.Molecular therapy. Oncology · 2026Article
- Urinary-free cortisol-based thresholds for differentiating ACTH-dependent Cushing: a Spanish validation study.The Journal of clinical endocrinology and metabolism · 2026Article
- Regulation of ultradian pulsatility and stress responses in the human hypothalamic-pituitary-adrenal axis.Journal of neuroendocrinology · 2026Article
- An observational study of menstrual function and related hormones before and after treatment of Cushing syndrome.Journal of the Endocrine Society · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Cancer incidence in endogenous hypercortisolism.Journal of endocrinological investigation · 2026Article
- Is Hypercortisolism Treatable? Which Patients Should Be Treated and How-A Practical Guide for Clinicians.Diabetes, obesity & metabolism · 2026Review
- Hypercortisolism: Causes, Consequences and Clinical Significance - A Review of Pathophysiology.Diabetes, obesity & metabolism · 2026Review
- International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome.The Journal of clinical endocrinology and metabolism · 2026Article
- Rare causes of exogenous Cushing's Syndrome: a challenge for endocrinologists.Journal of endocrinological investigation · 2026Review
- Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.The Journal of clinical endocrinology and metabolism · 2026Review
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.Endocrine reviews · 2026Review
- Article
- The value of targeting CXCR4 withEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy and safety of osilodrostat in patients with ectopic Cushing´s syndrome. a real-world study in Spain.Journal of endocrinological investigation · 2026Article
- Identification of High-Risk Individuals for Osteoporosis and Fragility Fractures in Cushing's Syndrome: A Promising Predictive Approach.Journal of clinical medicine · 2026Article
- Neutralization of acyl-CoA-binding protein attenuates glucocorticoid-mediated suppression of cancer immunosurveillance.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Consensus on the diagnosis of Cushing's disease: a collaborative statement from the Korean Endocrine Society and Japan Endocrine Society.Endocrine journal · 2026Article
- A Novel Evaluation of 24-hour Energy Metabolism in Cushing's Syndrome: The Metabolic Cost of Hypercortisolism.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing syndrome (CS) is a constellation of signs and symptoms caused by excessive exposure to exogenous or endogenous glucocorticoid hormones. Endogenous CS is caused by increased cortisol production by one or both adrenal glands (adrenal CS) or by elevated adrenocorticotropic hormone (ACTH) secretion from a pituitary tumour (Cushing disease (CD)) or non-pituitary tumour (ectopic ACTH secretion), which stimulates excessive cortisol production. CS is associated with severe multisystem morbidity, including impaired cardiovascular and metabolic function, infections and neuropsychiatric disorders, which notably reduce quality of life. Mortality is increased owing to pulmonary emboli, infection, myocardial infarction and cerebrovascular accidents. The clinical presentation is variable and because some CS signs and symptoms are common in the general population, the diagnosis might not be considered until many features have accumulated. Guidelines recommend screening patients with suspected CS with 24-h urine cortisol, bedtime salivary cortisol and/or 1 mg dexamethasone suppression test. Subsequently, determining the aetiology of CS is important as it affects management. The first-line therapy for all aetiologies of endogenous CS is surgical resection of the causal tissue, including corticotroph adenoma or ectopic tumour for ACTH-dependent CS or unilateral or bilateral adrenalectomy for adrenal CS. Second-line therapies include steroidogenesis inhibitors for any cause of CS, pituitary radiation (with or without steroidogenesis inhibitors) for CD, and bilateral adrenalectomy for ACTH-dependent causes of CS.
Indexed as
Identifiers
39848955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.